CD8A and neoplasm: If the expansion of the KLRG1+CD8+ subset population is an additional potential mechanism that helped establish better tumor growth control/regression in the combination Vax/aGITR/aPD-1 therapy, we wanted to determine whether targeting the KLRG1+CD8+ effector T cell subpopulation would lead to a loss of tumor growth control.